274 related articles for article (PubMed ID: 27596438)
1. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.
Richard G; Dalle S; Monet MA; Ligier M; Boespflug A; Pommier RM; de la Fouchardière A; Perier-Muzet M; Depaepe L; Barnault R; Tondeur G; Ansieau S; Thomas E; Bertolotto C; Ballotti R; Mourah S; Battistella M; Lebbé C; Thomas L; Puisieux A; Caramel J
EMBO Mol Med; 2016 Oct; 8(10):1143-1161. PubMed ID: 27596438
[TBL] [Abstract][Full Text] [Related]
2. Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.
Singh MK; Altameemi S; Lares M; Newton MA; Setaluri V
Sci Rep; 2022 Aug; 12(1):14395. PubMed ID: 35999349
[TBL] [Abstract][Full Text] [Related]
3. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
[TBL] [Abstract][Full Text] [Related]
4. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Yoshida T; Song L; Bai Y; Kinose F; Li J; Ohaegbulam KC; Muñoz-Antonia T; Qu X; Eschrich S; Uramoto H; Tanaka F; Nasarre P; Gemmill RM; Roche J; Drabkin HA; Haura EB
PLoS One; 2016; 11(1):e0147344. PubMed ID: 26789630
[TBL] [Abstract][Full Text] [Related]
5. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
Castro-Pérez E; Rodríguez CI; Mikheil D; Siddique S; McCarthy A; Newton MA; Setaluri V
Stem Cell Reports; 2019 Jul; 13(1):177-192. PubMed ID: 31231022
[TBL] [Abstract][Full Text] [Related]
6. ZEB1 transcription factor promotes immune escape in melanoma.
Plaschka M; Benboubker V; Grimont M; Berthet J; Tonon L; Lopez J; Le-Bouar M; Balme B; Tondeur G; de la Fouchardière A; Larue L; Puisieux A; Grinberg-Bleyer Y; Bendriss-Vermare N; Dubois B; Caux C; Dalle S; Caramel J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288462
[TBL] [Abstract][Full Text] [Related]
7. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
[TBL] [Abstract][Full Text] [Related]
8. ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions.
Durand S; Tang Y; Pommier RM; Benboubker V; Grimont M; Boivin F; Barbollat-Boutrand L; Cumunel E; Dupeuble F; Eberhardt A; Plaschka M; Dalle S; Caramel J
Oncogene; 2024 May; 43(20):1489-1505. PubMed ID: 38519642
[TBL] [Abstract][Full Text] [Related]
9. The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines.
Orellana-Serradell O; Herrera D; Castellón EA; Contreras HR
Asian J Androl; 2019; 21(5):460-467. PubMed ID: 30880686
[TBL] [Abstract][Full Text] [Related]
10. T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells.
Granados K; Hüser L; Federico A; Sachindra S; Wolff G; Hielscher T; Novak D; Madrigal-Gamboa V; Sun Q; Vierthaler M; Larribère L; Umansky V; Utikal J
Br J Cancer; 2020 Mar; 122(7):1023-1036. PubMed ID: 32063604
[TBL] [Abstract][Full Text] [Related]
11. Gambogic Acid Inhibits Melanoma through Regulation of miR-199a-3p/ZEB1 Signalling.
Liang L; Zhang Z; Qin X; Gao Y; Zhao P; Liu J; Zeng W
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):692-703. PubMed ID: 29959879
[TBL] [Abstract][Full Text] [Related]
12. AMBRA1 levels predict resistance to MAPK inhibitors in melanoma.
Di Leo L; Pagliuca C; Kishk A; Rizza S; Tsiavou C; Pecorari C; Dahl C; Pacheco MP; Tholstrup R; Brewer JR; Berico P; Hernando E; Cecconi F; Ballotti R; Bertolotto C; Filomeni G; Gjerstorff MF; Sauter T; Lovat P; Guldberg P; De Zio D
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2400566121. PubMed ID: 38870061
[TBL] [Abstract][Full Text] [Related]
13. ZEB1 Regulates Multiple Oncogenic Components Involved in Uveal Melanoma Progression.
Chen Y; Lu X; Montoya-Durango DE; Liu YH; Dean KC; Darling DS; Kaplan HJ; Dean DC; Gao L; Liu Y
Sci Rep; 2017 Mar; 7(1):45. PubMed ID: 28246385
[TBL] [Abstract][Full Text] [Related]
14. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
Vashisht Gopal YN; Gammon S; Prasad R; Knighton B; Pisaneschi F; Roszik J; Feng N; Johnson S; Pramanik S; Sudderth J; Sui D; Hudgens C; Fischer GM; Deng W; Reuben A; Peng W; Wang J; McQuade JL; Tetzlaff MT; Di Francesco ME; Marszalek J; Piwnica-Worms D; DeBerardinis RJ; Davies MA
Clin Cancer Res; 2019 Nov; 25(21):6429-6442. PubMed ID: 31439581
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer.
Yuan W; Ji J; Shu Y; Chen J; Liu S; Wu L; Zhou Z; Liu Z; Tang Q; Zhang X; Shu X
J Mol Med (Berl); 2019 Jan; 97(1):89-102. PubMed ID: 30460377
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.
Hong A; Moriceau G; Sun L; Lomeli S; Piva M; Damoiseaux R; Holmen SL; Sharpless NE; Hugo W; Lo RS
Cancer Discov; 2018 Jan; 8(1):74-93. PubMed ID: 28923912
[TBL] [Abstract][Full Text] [Related]
17. Notch signaling activation induces cell death in MAPKi-resistant melanoma cells.
Mikheil DM; Prabhakar K; Arshad A; Rodriguez CI; Newton MA; Setaluri V
Pigment Cell Melanoma Res; 2019 Jul; 32(4):528-539. PubMed ID: 30614626
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth.
Werden SJ; Sphyris N; Sarkar TR; Paranjape AN; LaBaff AM; Taube JH; Hollier BG; Ramirez-Peña EQ; Soundararajan R; den Hollander P; Powell E; Echeverria GV; Miura N; Chang JT; Piwnica-Worms H; Rosen JM; Mani SA
Oncogene; 2016 Nov; 35(46):5977-5988. PubMed ID: 27292262
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced expression of the RNA-binding protein HuR attenuates the adaptive response to BRAF inhibition in melanoma.
Merat R; Bugi-Marteyn A; Wrobel LJ; Py C; Daali Y; Schwärzler C; Liaudet N
Biochem Biophys Res Commun; 2019 Sep; 517(2):181-187. PubMed ID: 31279529
[TBL] [Abstract][Full Text] [Related]
20. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
Zhang G; Frederick DT; Wu L; Wei Z; Krepler C; Srinivasan S; Chae YC; Xu X; Choi H; Dimwamwa E; Ope O; Shannan B; Basu D; Zhang D; Guha M; Xiao M; Randell S; Sproesser K; Xu W; Liu J; Karakousis GC; Schuchter LM; Gangadhar TC; Amaravadi RK; Gu M; Xu C; Ghosh A; Xu W; Tian T; Zhang J; Zha S; Liu Q; Brafford P; Weeraratna A; Davies MA; Wargo JA; Avadhani NG; Lu Y; Mills GB; Altieri DC; Flaherty KT; Herlyn M
J Clin Invest; 2016 May; 126(5):1834-56. PubMed ID: 27043285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
